Dr. Kim takes over for Michael Sumner, MD, who has been in the role since 2013, according to an Oct. 26 press release.
Dr. Kim will be located at the company’s U.S. subsidiary in Morristown, N.J., and will lead the U.S. medical affairs department.
He will also work closely with the pharmaceutical team in Sweden on the development of Orexo’s AmorphOX platform, which focuses on innovative treatments for patients with substance abuse disorders.
Prior to his new role, Dr. Kim worked as a psychiatrist for 13 years before joining Biohaven Pharmaceuticals as its vice president and head of medical affairs.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
